From the FDA Drug Label
The mean age at study entry was 40 years (range 18-75 years of age). The mean age at study entry was 41 years (range 18-74 years of age)
The age limit for Nurtec is 18 years and above, as the clinical trials included patients with a range of 18-75 years of age 1.
From the Research
Nurtec ODT (rimegepant) is approved for use in adults aged 18 years and older for both the acute treatment of migraine and preventive treatment of episodic migraine, with no established upper age limit for its use in adults. The medication is not approved for use in children or adolescents under 18 years of age, as safety and efficacy have not been established in pediatric populations 2. Clinical trials primarily included adult patients, and there is limited data on its use in elderly patients (65 years and older). Nurtec works by blocking calcitonin gene-related peptide (CGRP) receptors, which are involved in migraine pain signaling. The standard dosing for acute treatment is 75 mg taken as needed, while for prevention, it's 75 mg every other day.
Some key points to consider when using Nurtec include:
- Patients with severe kidney or liver impairment may require dosage adjustments or should avoid the medication altogether, regardless of age 2.
- Always consult with a healthcare provider before starting Nurtec to ensure it's appropriate based on your specific age, health conditions, and other medications you may be taking.
- Rimegepant has been shown to be effective for the acute treatment of migraine in adults with a history of insufficient response to 1 or ≥2 triptans and in current triptan users 3.
- The efficacy of rimegepant on co-primary endpoints did not differ based on the number of insufficient triptan responses 3.
- Compared to triptans, rimegepant and other CGRP antagonists may offer an alternative with lower cardiovascular risks, although they may have lower odds ratios for pain freedom and pain relief at 2 hours 4.